Investigation of the immune infiltrate of metastatic melanoma under immune checkpoint inhibition

Trial Profile

Investigation of the immune infiltrate of metastatic melanoma under immune checkpoint inhibition

Not stated
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Ipilimumab/nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Oct 2017 New trial record
    • 09 Sep 2017 Results presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top